Bartek Tomasik: I’m Launching a New Study Called RAPSTAR
Bartek Tomasik, Assistant Professor at Medical University of Gdańsk, shared on X:
“Happy to share that I’m launching a new study called RAPSTAR – the first randomised, multicentre phase III trial comparing RAPN vs SABR in patients who are candidates for surgery. Designed and led in Poland, just got funding from Medical Research Agency and will start accrual soon!
Partial nephrectomy is the gold standard for early-stage kidney cancer. Stereotactic radiotherapy (SABR) is emerging (thanks to Shankar Siva and the FASTRACK II trial), but so far, only for patients who can’t be operated on.
RAPSTAR will be coordinated by Medical Research Agency in collaboration with UMK Torun with the support of PTU.
We will evaluate:
- Kidney function (eGFR)
- Local and distant control
- QoL
- Cost-effectiveness
We won’t just compare outcomes – we’ll compare entire care pathways.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023